342. Pharmacogenomics in alcohol use disorder: multi-omics meets brain organoids
Abstract Background We previously conducted an open label acamprosate trial (n=442) in patients with alcohol use disorder (AUD). Acamprosate is an FDA-approved medication for the treatment of AUD, however, only about 50% of patients will respond to acamprosate. To date, no biological measures are utilized to predict re...